A Phase 2 Study of Tislelizumab as Neoadjuvant Treatment of Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma.
Tislelizumab 作为新辅助治疗治疗不适合顺铂治疗的高危上尿路尿路上皮癌的 II 期研究。
期刊:Journal of Urology
影响因子:6.8
doi:10.1097/JU.0000000000004475
Huang Jiwei, Cai Xingyun, Ng Cheoklong, Luo Yuansheng, Chen Qiong, Wang Zaoyu, Qiao Keying, Kong Wen, Zhang Jin, Chen Yonghui, Zhang Wei, Zhang Jiyang, Zhang Dadong, Wu Guangyu, Chen Haige, Xue Wei